TGTX.O

TGTX's capital structure is characterized by a market cap of $5.53 billion and a price-to-book ratio of 8.53, indicating a premium valuation relative to its book value. The company's liquidity position is mixed, with $79.15 million in cash and equivalents but a negative net cash position after subtracting $245.65 million in long-term debt. Free cash flow of $447.02 million suggests strong cash generation, but operating cash flow is negative at -$24.77 million, signaling potential near-term operational challenges. Profitability metrics show a return on equity (ROE) of 69.01% and a return on assets (ROA) of 42.06%, both significantly above the industry median for biotechnology firms. The company's gross margin of 83.6% (calculated from gross profit of $515.57 million on revenue of $616.29 million) is robust, but its operating margin of 19.99% is lower, reflecting high R&D and SG&A expenses typical in the sector. Geographically, TGTX's revenue is concentrated in the United States, with no material international operations disclosed. The company's product portfolio is currently centered on Tavneos, with no other commercialized products contributing to revenue. This concentration in a single product and market increases exposure to regulatory, reimbursement, and competitive risks. Growth trajectory is positive, with revenue of $616.29 million in the latest period. Analysts project a mean price target of $44.33, implying a 22.7% upside from the current market price of $36.10. The company's capital expenditure of -$214,000 suggests minimal investment in physical assets, consistent with a biotech firm focused on R&D rather than manufacturing infrastructure. Risk factors include a medium liquidity rating due to the negative net cash position and a debt-to-equity ratio of 0.38. The company has a low dilution risk, with basic and diluted shares outstanding aligned at 153.09 million. No recent dilutive events are disclosed, and the risk assessment does not flag near-term dilution pressure. Recent events include the continued commercialization of Tavneos and ongoing clinical trials for additional indications. The company has not disclosed any material regulatory or litigation risks in the latest filings, but the biotech sector is inherently subject to high R&D failure rates and regulatory uncertainty.